ID
Bron
Verkorte titel
Aandoening
Barrett's esophagus; Barrett's related neoplasia
Ondersteuning
Academic Medical Center Amsterdam (AMC)
Collaborating centers:
• Sint Antonius Hospital Nieuwegein
• Catharina Hospital, Eindhoven
• University Medical Center, Utrecht
• Isala Clinics, Zwolle
• Erasmus Medical Center, Rotterdam
• Haga Hospital, Den Haag
• University Medical Center, Groningen
Onderzoeksproduct en/of interventie
Uitkomstmaten
Primaire uitkomstmaten
The primary objective is to determine the proportion of patients with successful eradication of BE after endoscopic therapy. The primary endpoint will be the proportion of patients with a successful complete eradication of Barrett’s neoplasia (CE-Neo) after the treatment phase.
Achtergrond van het onderzoek
• Esophageal adenocarcinoma (EAC) is highly lethal with a 5-years survival of only 10-15%. The main histologic risk factor for development of EAC is the presence of Barrett’s esophagus (BE). BE can develop from non-dysplastic BE, to low (LGD) and high grade dysplasia (HGD) and, eventually, EAC. Currently, a combined approach of endoscopic resection and endoscopic ablation therapy is the established treatment for eradicating Barrett’s related neoplasia. The organization of BE care in the Netherlands is unique when compared to the rest of the world: the care for all BE patients is centralized in eight Barrett Expert Centers (BEC) with an intensive cooperation and, as a result, homogeneous diagnosis and treatment. However, the overall outcomes for these centers are unknown. The purpose of the study is to determine the state-of-the-art results of endoscopic treatment for Barrett’s esophagus.
Onderzoeksopzet
* First treatment endoscopy
* End of the endoscopic treatment phase, defined as the last endoscopy with endoscopic treatment performed.
* Last follow-up endoscopy
Onderzoeksproduct en/of interventie
Endoscopic treatment of Barrett's esophagus by means of endoscopic resection (either endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD)), radiofrequency ablation (RFA) or a combination thereof.
Publiek
Bldg. C2-210, Meibergdreef
J.J.G.H.M. Bergman
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5669111
j.j.bergman@amc.uva.nl
Wetenschappelijk
Bldg. C2-210, Meibergdreef
J.J.G.H.M. Bergman
Amsterdam 1105 AZ
The Netherlands
+31 (0)20 5669111
j.j.bergman@amc.uva.nl
Belangrijkste voorwaarden om deel te mogen nemen (Inclusiecriteria)
1) Males or females, all ages
2) Presence of Barrett’s esophagus, with presence of intestinal metaplasia in histologic assessment.
3) Referred for work-up in a BEC from 1/1/2007 to the moment of data collection.
4) Scheduled for endoscopic eradication therapy of BE
5) No written or oral refusal to use subject’s data
Belangrijkste redenen om niet deel te kunnen nemen (Exclusiecriteria)
1) Objection against participation in this study, through an opt-out card or e-mail
2) Referral for surgery after the work-up endoscopy for advanced EAC
3) Presence of non-dysplastic BE without an indication for treatment
Opzet
Deelname
Opgevolgd door onderstaande (mogelijk meer actuele) registratie
Geen registraties gevonden.
Andere (mogelijk minder actuele) registraties in dit register
Geen registraties gevonden.
In overige registers
| Register | ID |
|---|---|
| NTR-new | NL7039 |
| NTR-old | NTR7244 |
| Ander register | METC AMC : W18_086 |